Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP-03 in Advanced Malignant Solid Tumors
NCT05203601Phase 1Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIBP-03 in solid tumor, head and neck squamous cell carcinoma (HNSCC) and breast cancer (3 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoints: Adverse Events, Serious Adverse Events and 6 more. Started Nov 2020; status: completed.
02
Drugs
SIBP-03
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)breast cancer
Beyond the preview
Go deeper on NCT05203601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203601.